News

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

In this edition of the APAC Recap, Erin Pardee, PA-C, discusses the American Society of Preventive Cardiology 2024 Congress on CVD Prevention with Viet Le, DMSc, PA-C.

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Banty discusses recent advancements in the ulcerative colitis and Crohn disease treatment landscapes, explaining how to navigate the growing number of treatment options.

Janovsky explains the importance of nutrition and dietary interventions in MASH and cirrhosis management, reviewing how providers can discuss both with patients.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

This approval expands the drug’s age range and follows recent positive phase 3 findings on dupilumab treatment for patients aged 12 to 17 with CRSwNP.

Richards describes the utility of different NITs in primary and specialty care for risk-stratifying patients with MASH and fibrosis.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

A new study found cannabis-containing cream may be effective at alleviating itch in patients with chronic kidney disease (CKD)-associated pruritus with no adverse events.

Solomon explains how to navigate the growing Crohn disease treatment armamentarium and the importance of treatment positioning.

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.

These data highlighted dupilumab’s potential as a means to break the ‘itch–scratch cycle’ in those with chronic prurigo, with disease remission induced in a subset.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

Iordache reviews complications of diagnosing hepatobiliary disease in pregnancy and explains how these patients typically present.

This marketing authorization by the FDA allows the Hearing Aid Feature to be implemented alongside compatible Apple AirPod Pro headphones.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

The APAC Recap is a new multimedia series created through a partnership between APAC and HCPLive where members of the Academy of Physician Associates have peer-to-peer discussions centered around recent scientific congresses and meetings.

This analysis may help to inform research evaluating the value of obstructive sleep apnea treatments designed to minimize cardiovascular risk as well as related deaths among older patients.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

Martinez de Andino reviews key considerations for the management of DGBI with brain-gut behavioral therapy and neuromodulators.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.